Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction.

ABSTRACT:

Background

Angiotensin receptor blocker and a neprilysin inhibitor (ARNI) has emerged as an innovative therapy for patients of heart failure with reduced ejection fraction (HFrEF). The purpose of this study was to assess the safety and tolerability of Sacubitril/Valsartan in patient with HFrEF in Pakistani population.

Methods

This proof-of-concept, open label non-randomized clinical trial was conducted at a tertiary care cardiac center of Karachi, Pakistan. Patients with HFrEF were prescribed with Sacubitril/Valsartan and followed for 12 weeks for the assessment of safety and tolerability. Safety measures included incidence of hypotension, renal dysfunction, hyperkalemia, and angioedema.

Results

Among the 120 HFrEF patients, majority were male (79.2%) with means age o

SUBMITTER: Khan MN 

PROVIDER: S-EPMC10012729 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature